Chemoradiotherapy

Phase 3Small molecule

BBetta Pharmaceuticals Co., Ltd.

Chemoradiotherapy is one of 14 small molecule programs targeting Total Neoadjuvant Therapy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Total Neoadjuvant TherapyRecruiting

Total Neoadjuvant TherapyPhase 3

Recruiting

Competition

Competitive Landscape

13 competitors in Total Neoadjuvant Therapy

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 2

3 2

Beyfortus

BeiGene

Phase 2

1 3

Avastin

Roche

Phase 2

1 4

Serplulimab

Shanghai Henlius Biotech

Phase 3

1 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

2 6

Mfolfox6

Roche

Phase 2

1 7

Pucotenlimab

SSun Yat-sen University

Phase 2

1 8

PD-1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

1 9

GLP-1 Receptor Agonist

Boehringer Ingelheim

Phase 2

1 10

Envafolimab

TTracon Pharmaceuticals Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2/3Recruiting

Total Neoadjuvant Therapy

NCT06758830

Q2 2030

Phase 2Recruiting

Efficacy and Safety of Short-Course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for Pmmr Locally Advanced Rectal Cancer

NCT07448077

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer

Unknown status·BBetta Pharmaceuticals Co., Ltd.·Phase 2·NCT02215356·120 enrolled

Total Neoadjuvant Therapy1 trial

Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.

Recruiting·—·Phase 2/3·NCT06758830·400 enrolled

Adjuvant Treatment1 trial

Phase I Study of CCRT as Adjuvant Treatment for Stage II/III Operable Rectal Cancer.

Unknown status·—·Phase 1·NCT02277158·18 enrolled

Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer1 trial

Short-Course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT07448077·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Chemoradiotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chemoradiotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chemoradiotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Betta Pharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBetta Pharmaceuticals Co., Ltd.

Chemoradiotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Q2 2030

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Total Neoadjuvant Therapy1 trial

Adjuvant Treatment1 trial

Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer1 trial

References

Drug Info

Quick Facts

Related News